Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSLN-CAR-IL7-IL7Rα NK cells
- Development stage
- Preclinical
- Lead developer
- Dana-Farber Cancer Institute
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
MSLN-CAR-IL7-IL7Rα NK cells, also known as the **Buddy-CAR system**, are engineered natural killer (NK) cells designed to treat mesothelin-expressing solid tumors, such as pancreatic cancer. Developed at the Dana-Farber Cancer Institute, these cells are modified with a chimeric antigen receptor (CAR) targeting mesothelin (MSLN) and are further engineered to both secrete interleukin-7 (IL7) and express the interleukin-7 receptor alpha (IL7Rα). This dual modification overcomes the natural lack of IL7Rα on mature NK cells, allowing for autocrine "cis-activation" that significantly enhances NK cell proliferation, survival, and cytotoxicity. Additionally, the secreted IL7 provides "trans-activation" to bystander tumor-infiltrating T cells within the immunosuppressive tumor microenvironment, promoting their proliferation and preventing exhaustion. Preclinical studies have demonstrated superior trafficking, proliferation, and anti-tumor responses in xenograft mouse models compared to standard CAR-NK constructs.
- Other names
- Mesothelin-CAR-IL7-IL7Rα NK cellsMSLN-CAR-IL7-IL7Ralpha NK cellsMSLN-CAR-IL-7-IL7Ralpha NK cellsMSLN-CAR-IL 7-IL7Ralpha NK cells
02
Targets
IL7R (Interleukin-7 Receptor)Mesothelin
Beyond the preview
Go deeper on MSLN-CAR-IL7-IL7Rα NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MSLN-CAR-IL7-IL7Rα NK cells.